BIO Business Solutions Cost-Savings Program | FDA issues draft guidance on post-approval drug safety | Lawmakers introduce FAST Act to accelerate approval process
March 13, 2012
Bio SmartBrief
The Latest From BIO ...
BIO Business Solutions Cost-Savings Program
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
Today's Top Story
FDA issues draft guidance on post-approval drug safety
The FDA is seeking public comment on guidance detailing a system for handling postmarket drug safety issues, including drug quality and serious adverse events. The draft guidance establishes a three-tiered system of classifying the severity of problems. (U.K.) (3/12) 
LinkedIn Twitter Facebook Google+ Email
Empower Your Company: Identify New Product Opportunities. Learn from our years of experience helping leading companies shape their product strategy. Snowfish has developed unique approaches for uncovering opportunities for new and existing products. We identify strategic partners, assess clinical development hurdles, and analyze market and competitive threats. Let us share our insights, download our free whitepapers.
Health Care & Policy
Lawmakers introduce FAST Act to accelerate approval process
Reps. Cliff Stearns, R-Fla., and Edolphus Towns, D-N.Y., have introduced a bill that would speed up the commercialization of new drugs for serious diseases. The Faster Access to Specialized Treatments Act would update and systematize the accelerated-approval program of the FDA. BIO President and CEO Jim Greenwood praised the proposal, saying it would allow biotech firms to bring newly developed drugs to those who need them "at the earliest point in time."
The Gainesville Sun (Fla.) (3/11) 
LinkedIn Twitter Facebook Google+ Email
FDA approves Organogenesis' cell-based product for gum surgery
Organogenesis has received FDA approval to market Gintuit, its cell-based product designed to replace receding gum tissue during dental gum surgeries. Gintuit is composed of donated skin cells attached to bovine collagen. Organogenesis CEO Geoff MacKay said the decision marks the agency's first approval of a mass-produced cell treatment and its first OK of regenerative tissue for an oral condition.
The Boston Globe (tiered subscription model) (3/9) 
LinkedIn Twitter Facebook Google+ Email
Foundation partners with Array on cancer drug responses
Foundation Medicine has signed a deal to use its genome sequencing technology to help pinpoint patients who may potentially respond to cancer drugs developed by Array BioPharma. The company has similar agreements with pharmaceutical firms Johnson & Johnson, Novartis, Sanofi and Celgene.
Clinica (subscription required) (3/8) 
LinkedIn Twitter Facebook Google+ Email
Researchers see hope for growing organs from stem cells
Swedish and American researchers have developed a technique that could be used to turn patients' stem cells into organs and complex tissue. Paolo Macchiarini writes in The Lancet that animal tissue could be used as scaffolds to grow organs, but he cautions that a strong commitment to safety is necessary. Macchiarini has been involved in two trachea transplants using tissue engineered from patients' cells.
The Independent (London) (tiered subscription model) (3/9),  The Sydney Morning Herald (Australia) (3/12) 
LinkedIn Twitter Facebook Google+ Email
Company & Financial News
Valeant buys minority interest in Brazil's Pele Nova
Valeant Pharmaceuticals International spent less than $10 million for a 19.9% stake in Pele Nova Biotecnologia, a Brazilian research firm involved in tissue regeneration. The deal entitles Valeant to representation on Pele Nova's board and a lower royalty rate for wound-healing product Regederm. Valeant also gets rights to all of Pele Nova's future products in Brazil and the first right to refuse worldwide product rights.
Winnipeg Free Press (Manitoba) (tiered subscription model)/The Canadian Press (3/12) 
LinkedIn Twitter Facebook Google+ Email
HemaQuest raises $13 million for sickle cell disease drug
HemaQuest Pharmaceuticals secured $13 million in an extension of a Series B funding round. The company will use the money for a Phase IIb trial of its lead drug candidate, HQK-1001, in patients with sickle cell disease.
Xconomy/San Diego (3/12) 
LinkedIn Twitter Facebook Google+ Email
Global Developments
Sanofi and Spanish genomics center unite on rare-disease research
Sanofi and Spain's Center for Genomic Regulation plan to study hereditary and rare disorders through medical genetics, computational biology and epigenetics. The multidisciplinary approach "will bring added value to basic research by offering a better understanding of disease for pathologies such as tuberculosis and cancer and also by helping to develop new therapeutic solutions for their treatment," according to a joint statement.
PharmaTimes (U.K.) (3/9) 
LinkedIn Twitter Facebook Google+ Email
BioLineRx obtains European patent for schizophrenia treatment
BioLineRx was awarded a European patent for BL-1020 and its use as a schizophrenia treatment effective through Sept. 29, 2022. Preclinical and clinical trials showed that BL-1020 has a good safety profile and treats the disease's symptoms.
Pharmaceutical Business Review Online (3/9) 
LinkedIn Twitter Facebook Google+ Email
Business Tips and Advice
Sponsored Content from American Express
Food & Agriculture
Researchers developing "superjuice" from biotech orange
Spanish scientists have infused the genes that give the Sicilian blood orange its red pigments into biotech Valencia orange seedlings to create an orange "superjuice" that they say could help fight obesity, heart disease and irritable bowel syndrome. The seedlings are being grown at a Spanish research center and are expected to produce oranges this year.
The Independent (London) (tiered subscription model) (3/13) 
LinkedIn Twitter Facebook Google+ Email
Industrial & Environmental
Groups throw support behind Stabenow amendment
Several biofuel groups are calling on U.S. senators to support an amendment by Sen. Debbie Stabenow, D-Mich., that would renew tax incentives for cellulosic ethanol and biodiesel. "This is about creating good-paying jobs and building up a U.S. energy industry that will help end our dangerous vulnerability to the kinds of oil price spikes we're seeing now," said Anne Steckel, vice president of federal affairs for the National Biodiesel Board. (3/11) 
LinkedIn Twitter Facebook Google+ Email
News From BIO
Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
To avoid criticism do nothing, say nothing, be nothing.
Elbert Hubbard,
American writer, artist and philosopher
LinkedIn Twitter Facebook Google+ Email
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Meryl Harold
P: 202.407.7828
Editor  -  Tara Rosenzweig
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information